article thumbnail

Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development

Fierce Pharma

“Our next question will come from Andrew Baum with Citi.” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities.

article thumbnail

VivoPlex raises funding to develop intra-uterine sensor

pharmaphorum

to develop an intra-uterine sensor system and generate clinical data that could be used for European approval. The Future Fund participated in the second tranche of the fundraising alongside other investors, unlocking matched financing and helping to drive the business forward towards commercialisation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading pharmaceutical solid dose (commercial dose) manufacturing companies in contract marketing

Pharmaceutical Technology

Streamlined development, flexibility in manufacturing, and improved product quality at reduced costs, while gaining access to capabilities and capacity are some of the factors fuelling the pharmaceutical solid dosage contract manufacturing market.

article thumbnail

How Are Biopharma Companies Evaluating Partnerships in the Rare Disease Space?

Camargo

Thomas Kassberg, Chief Business Officer, Ultragenyx. Thomas Kassberg, Chief Business Officer, Ultragenyx. I think you really need to get the feedback directly from patients and then incorporate that feedback as you think about how you’re going to develop the product to be successful. Tom Kassberg, Ultragenyx. Dan Curran, Takeda.

article thumbnail

Ferrer secures worldwide rights to PSP drug

Drug Discovery World

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need. The disease gets progressively worse, causing severe disability within three to five years of onset.

Drugs 52
article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. His research focuses on the development of big data machine learning for tracking the health of complex systems. But what does it take to implement these innovations?

article thumbnail

Seqster launches new cloud version of virtual trial data tool

pharmaphorum

Healthcare technology firm Seqster has introduced a new version of its service that aims to help pharma companies work with patients’ data while on virtual clinical trials. Seqster announced the new version of its platform had been launched on the Microsoft Azure cloud at the annual JP Morgan Healthcare Conference. The new Seqster 7.1

Trials 52